UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2021 Earnings Conference Call March 24, 2022 9:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chairman and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President, Product Portfolio Strategy and Business Development Frederic Lombard - Senior Vice President and Chief Financial Officer Conference Call Participants Daina Graybosch - SVB Leerink Liisa Bayk ...

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2021 Results Earnings Conference Call November 16, 2021 8:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President, Product Portfolio Strategy and Business Development Conference Call Participants Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Leerink Keyur Parekh - Goldman Sachs Olga Smolentseva - Bryan Garnie ...

Third Quarter 2021 Business Update November 16, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potent ...

Innate Pharma S.A. (OTCPK:IPHYF) Q2 2021 Earnings Conference Call September 15, 2021 8:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - EVP & Chief Medical Officer Frédéric Lombard - SVP, Chief Financial Officer Henry Wheeler - IR Conference Call Participants Daina Graybosch - SVB Leerink Yigal Nochomovitz - Citigroup Graig Suvannavejh - Goldman Sachs Operator Good day, and thank you for standing by, and welcome to the Innate Pharma Half Year Results Con ...

Half Year 2021 Business Update September 15, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential ...

Innate Pharma S.A. (OTCPK:IPHYF) Q1 2021 Earnings Conference Call May 11, 2021 9:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - Executive VP & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Leerink Swayampakula Ramakanth - H.C. Wainwright Liisa Bayko - Evercore Operator Good day, and thank you for standing by, and welcome to the Innate Pharma 2021 First Quarter Business Update Conference Call. [Op ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission File Number 001-39084 Innate Pharma SA (Exact name of registrant as specified in its charter and translation of registrant's name into English) OR ☒ ANNUAL REPORT PURS ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) FORM 20-F For the fiscal year ended December 31, 2019 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ (Jurisdiction of incorporation or organi ...

Innate Pharma SA (OTCPK:IPHYF) Q4 2019 Results Conference Call March 10, 2020 9:00 AM ET Company Participants Danielle Spangler - Head of Investor Relations Mondher Mahjoubi - Chairman of the Executive Board and Chief Executive Officer Dr. Pierre Dodion - EVP and Chief Medical Officer Laure-Hélène Mercier - EVP and Chief Financial Officer Yannis Morel - EVP of Product Strategy Conference Call Participants Samantha Semenkow - Citigroup Swayampakula Ramakanth - H.C. Wainwright Daina Graybosch - SVB Leerink O ...